Christopher Rohde1,2, Jakob S Knudsen3,4, Norbert Schmitz5, Søren Dinesen Østergaard6,3, Reimar W Thomsen3,4. 1. Department of Affective Disorders, Aarhus University Hospital - Psychiatry, Aarhus, Denmark. CHRROH@rm.dk. 2. Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. CHRROH@rm.dk. 3. Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. 4. Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark. 5. Douglas Mental Health University Institute, McGill University, Montreal, QC, Canada. 6. Department of Affective Disorders, Aarhus University Hospital - Psychiatry, Aarhus, Denmark.
Abstract
AIMS/HYPOTHESIS: We aimed to assess whether current antidepressant therapy or a history of hospital-diagnosed depression affects diabetes treatment initiation, adherence, and HbA1c and LDL-cholesterol target achievement. METHODS: In this register-based study, we included all individuals from Central and Northern Denmark with newly diagnosed type 2 diabetes, defined as a first-ever HbA1c measurement of ≥48 mmol/mol (6.5%), between 2000 and 2016. Individuals either diagnosed with depression at a psychiatric hospital in the 2 years prior to their diabetes diagnosis or currently receiving treatment with an antidepressant were compared with individuals with type 2 diabetes, but without depression treatment or previous history of depression. Outcome measures included initiation of glucose-lowering drugs and lipid-modifying agents, adherence to these medications (medication possession ratio >80%), and HbA1c (<53 mmol/mol [7%]) and LDL-cholesterol (<2.6 mmol/l) target achievement. The assessment of association between depression or antidepressant treatment and these outcomes was conducted using regression analyses with adjustment for potential confounders. RESULTS: We included a total of 87,650 individuals with first-ever HbA1c-diagnosed type 2 diabetes, of whom 0.9% (n = 784) had hospital-diagnosed depression and 11.4% (n = 9963) currently received antidepressant treatment. Compared with those without depression treatment, treatment with an antidepressant was associated with increased likelihood of glucose-lowering drug initiation (HR 1.39 [95% CI 1.34, 1.44]) and adherence (OR 1.27 [95% CI 1.18, 1.36]), lipid-modifying agent initiation (HR 1.17 [95% CI 1.11, 1.23]) and adherence (OR 1.25 [95% CI 1.09, 1.43]), and achievement of LDL (OR 1.08 [95% CI 1.03, 1.14]) but not HbA1c target (OR 0.99 [95% CI 0.93, 1.06]). The findings were similar for individuals who had hospital-diagnosed depression. CONCLUSIONS/ INTERPRETATION: In individuals with newly diagnosed type 2 diabetes, antidepressant treatment and depression were associated with improved diabetes treatment quality. Graphical abstract.
AIMS/HYPOTHESIS: We aimed to assess whether current antidepressant therapy or a history of hospital-diagnosed depression affects diabetes treatment initiation, adherence, and HbA1c and LDL-cholesterol target achievement. METHODS: In this register-based study, we included all individuals from Central and Northern Denmark with newly diagnosed type 2 diabetes, defined as a first-ever HbA1c measurement of ≥48 mmol/mol (6.5%), between 2000 and 2016. Individuals either diagnosed with depression at a psychiatric hospital in the 2 years prior to their diabetes diagnosis or currently receiving treatment with an antidepressant were compared with individuals with type 2 diabetes, but without depression treatment or previous history of depression. Outcome measures included initiation of glucose-lowering drugs and lipid-modifying agents, adherence to these medications (medication possession ratio >80%), and HbA1c (<53 mmol/mol [7%]) and LDL-cholesterol (<2.6 mmol/l) target achievement. The assessment of association between depression or antidepressant treatment and these outcomes was conducted using regression analyses with adjustment for potential confounders. RESULTS: We included a total of 87,650 individuals with first-ever HbA1c-diagnosed type 2 diabetes, of whom 0.9% (n = 784) had hospital-diagnosed depression and 11.4% (n = 9963) currently received antidepressant treatment. Compared with those without depression treatment, treatment with an antidepressant was associated with increased likelihood of glucose-lowering drug initiation (HR 1.39 [95% CI 1.34, 1.44]) and adherence (OR 1.27 [95% CI 1.18, 1.36]), lipid-modifying agent initiation (HR 1.17 [95% CI 1.11, 1.23]) and adherence (OR 1.25 [95% CI 1.09, 1.43]), and achievement of LDL (OR 1.08 [95% CI 1.03, 1.14]) but not HbA1c target (OR 0.99 [95% CI 0.93, 1.06]). The findings were similar for individuals who had hospital-diagnosed depression. CONCLUSIONS/ INTERPRETATION: In individuals with newly diagnosed type 2 diabetes, antidepressant treatment and depression were associated with improved diabetes treatment quality. Graphical abstract.
Authors: Jessica L Harding; Meda E Pavkov; Dianna J Magliano; Jonathan E Shaw; Edward W Gregg Journal: Diabetologia Date: 2018-08-31 Impact factor: 10.122
Authors: Wayne J Katon; Carolyn Rutter; Greg Simon; Elizabeth H B Lin; Evette Ludman; Paul Ciechanowski; Leslie Kinder; Bessie Young; Michael Von Korff Journal: Diabetes Care Date: 2005-11 Impact factor: 19.112
Authors: A Nouwen; M C Adriaanse; K van Dam; M M Iversen; W Viechtbauer; M Peyrot; I Caramlau; A Kokoszka; K Kanc; M de Groot; G Nefs; F Pouwer Journal: Diabet Med Date: 2019-07-31 Impact factor: 4.359
Authors: Chao-Yi Wu; Lauren Terhorst; Jordan F Karp; Elizabeth R Skidmore; Juleen Rodakowski Journal: Diabetes Care Date: 2018-08-02 Impact factor: 19.112
Authors: Elizabeth H B Lin; Wayne Katon; Michael Von Korff; Carolyn Rutter; Greg E Simon; Malia Oliver; Paul Ciechanowski; Evette J Ludman; Terry Bush; Bessie Young Journal: Diabetes Care Date: 2004-09 Impact factor: 19.112
Authors: Mark D Sullivan; Patrick O'Connor; Patricia Feeney; Don Hire; Debra L Simmons; Dennis W Raisch; Lawrence J Fine; K M Venkat Narayan; Mohammad K Ali; Wayne J Katon Journal: Diabetes Care Date: 2012-05-22 Impact factor: 19.112
Authors: Jeffrey F Scherrer; Lauren D Garfield; Timothy Chrusciel; Paul J Hauptman; Robert M Carney; Kenneth E Freedland; Richard Owen; William R True; Patrick J Lustman Journal: Diabetes Care Date: 2011-06-16 Impact factor: 19.112
Authors: Emma A Nieuwenhuijse; Jeroen N Struijs; Stephen P Sutch; Mattijs E Numans; Rimke C Vos Journal: Diabet Med Date: 2022-04-01 Impact factor: 4.213